Keywords: Pfizer, Athersys, MultiStem, IBD drug, Licensing, Durata, Vicuron

Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid

Article | 22 December 2009

Print This

US stem-cell specialist Athersys’ shares rocketed almost 200% to $2.96 after it revealed yesterday that it has entered into an agreement with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in